Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

被引：0
|
作者：
Andrew D. Simmons
Minh Nguyen
Elias Pintus
机构：
[1] Translational Medicine,
[2] Clovis Oncology,undefined
[3] Inc.,undefined
[4] Berkshire Cancer Centre,undefined
[5] Royal Berkshire NHS Foundation Trust,undefined
[6] Guy’s Hospital,undefined
来源：
BMC Cancer | / 20卷
关键词：
BRCA; Prostate cancer; PARP inhibitor; Poly (ADP-ribose) polymerase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation
    Tao, Haitao
    Liu, Sisi
    Huang, Di
    Han, Xiao
    Wu, Xue
    Shao, Yang W.
    Hu, Yi
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (02): : 612 - 617
  • [22] Next generation sequencing of BRCA1 and BRCA2 genes in ovarian tumors captures all germline mutations and expands the potential treatment group for the PARP inhibitor olaparib
    Timms, K.
    Neff, C.
    Morris, B.
    Hodgson, D.
    Orr, M.
    Zhongwu, L.
    Fielding, A.
    Dougherty, B.
    Spencer, S.
    Robertson, J.
    Barrett, C.
    Gutin, A.
    Lanchbury, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S100 - S101
  • [23] Germline BRCA2 mutation in a patient with fallopian tube carcinoma: A case report
    Rose, PG
    Shrigley, R
    Wiesner, GL
    GYNECOLOGIC ONCOLOGY, 2000, 77 (02) : 319 - 320
  • [24] Double Heterozygous Mutations in the BRCA2 and ATM Genes: A Case Report and Review of the Literature
    Duzkale Teker, Neslihan
    Eyerci, Nilnur
    BREAST CARE, 2021, 16 (04) : 412 - 416
  • [25] Case report: Antenatal diagnostic of a polymalformative syndrome due to biallelic BRCA2 mutations
    Anquetil, Aude
    Khung Savatovsky, Suonavy
    Gavard, Laurent
    Bazin, Anne
    Guimiot, Fabien
    Dubourg, Christele
    Mandelbrot, Laurent
    Picone, Olivier
    CLINICAL CASE REPORTS, 2021, 9 (09):
  • [26] Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family
    Ying Liao
    Chunhua Tu
    Xiaoxia Song
    Liping Cai
    Journal of Assisted Reproduction and Genetics, 2020, 37 : 1489 - 1495
  • [27] Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family
    Liao, Ying
    Tu, Chunhua
    Song, Xiaoxia
    Cai, Liping
    JOURNAL OF ASSISTED REPRODUCTION AND GENETICS, 2020, 37 (06) : 1489 - 1495
  • [28] BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
    Pishvaian, Michael J.
    Biankin, Andrew V.
    Bailey, Peter
    Chang, David K.
    Laheru, Daniel
    Wolfgang, Christopher L.
    Brody, Jonathan R.
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : 1021 - 1026
  • [29] BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
    Michael J Pishvaian
    Andrew V Biankin
    Peter Bailey
    David K Chang
    Daniel Laheru
    Christopher L Wolfgang
    Jonathan R Brody
    British Journal of Cancer, 2017, 116 : 1021 - 1026
  • [30] Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models
    Clark, Caroline C.
    Weitzel, Jeffrey N.
    O'Connor, Timothy R.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (09) : 1948 - 1958
12345